A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

NCT02347657 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: VX-661 Plus Ivacaftor Combination
DRUG: Ivacaftor
DRUG: VX-661 Plus Ivacaftor Combination Placebo
DRUG: Ivacaftor placebo

Sponsor

Vertex Pharmaceuticals Incorporated